Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MARY ANN PICONE

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1295888030
CMS profile
911929
Location
TEANECK, NJ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$235,960.41

296 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 4 of 6; records 151–200 of 296 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MARY ANN PICONE

NPI 1295888030 · CMS profile ID 911929

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

TEANECK, NJ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 6; records 151–200 of 296 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1295888030?year=2024&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MARY ANN PICONE, NPI 1295888030, CMS profile ID 911929. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 6; records 151–200 of 296 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1295888030?year=2024&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). MARY ANN PICONE, NPI 1295888030, CMS profile ID 911929. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 6; records 151–200 of 296 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1295888030?year=2024&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
MARY ANN PICONE, NPI 1295888030, CMS profile ID 911929, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 6; records 151–200 of 296 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1295888030?year=2024&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

296 matching records · $235,960.41 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 296 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–200 of 296.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Celgene Corporation $58.5105/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101104050 CMS
GENZYME CORPORATION $48.9905/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139609608 CMS
Celgene Corporation $15.5705/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101104044 CMS
Celgene Corporation $0.4905/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101104046 CMS
Philips North America LLC $17.1905/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146913786 CMS
TG Therapeutics, Inc. $5.4005/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136889688 CMS
GENZYME CORPORATION $120.2905/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139609638 CMS
GENZYME CORPORATION $3,537.0005/21/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139609640 CMS
GENZYME CORPORATION $533.0605/21/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139609642 CMS
Novartis Pharmaceuticals Corporation $21.3205/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087218543 CMS
TG Therapeutics, Inc. $125.0005/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136889736 CMS
TG Therapeutics, Inc. $3,712.5005/14/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136889754 CMS
TG Therapeutics, Inc. $1,058.2605/14/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136889758 CMS
TG Therapeutics, Inc. $133.8305/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136889798 CMS
TG Therapeutics, Inc. $3,712.5005/12/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136889838 CMS
TG Therapeutics, Inc. $762.6305/12/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136889842 CMS
TG Therapeutics, Inc. $10.7305/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136889690 CMS
EMD Serono, Inc. $43.0305/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120242331 CMS
Genentech USA, Inc. $3,450.0005/07/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133064136 CMS
TG Therapeutics, Inc. $8.1005/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136889696 CMS
E.R. Squibb & Sons, L.L.C. $2,618.0005/06/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101303973 CMS
TG Therapeutics, Inc. $134.0105/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136889784 CMS
TG Therapeutics, Inc. $3,712.5005/06/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136889844 CMS
TG Therapeutics, Inc. $125.0005/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136889716 CMS
TG Therapeutics, Inc. $196.6505/02/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136889728 CMS
TG Therapeutics, Inc. $4,387.5005/02/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136889730 CMS
TG Therapeutics, Inc. $306.2105/02/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136889734 CMS
TG Therapeutics, Inc. $1,564.5205/02/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136889748 CMS
TG Therapeutics, Inc. $3,712.5005/01/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136889714 CMS
TG Therapeutics, Inc. $983.9205/01/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136889746 CMS
Celgene Corporation $14.6104/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101104040 CMS
Celgene Corporation $1.4404/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101104042 CMS
TG Therapeutics, Inc. $31.0704/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136889684 CMS
TG Therapeutics, Inc. $4,650.0004/26/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136889706 CMS
TG Therapeutics, Inc. $116.7604/26/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136889708 CMS
TG Therapeutics, Inc. $556.2004/26/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136889718 CMS
TG Therapeutics, Inc. $2,036.4904/25/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136889712 CMS
TG Therapeutics, Inc. $329.3004/25/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136889738 CMS
TG Therapeutics, Inc. $225.9004/25/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136889742 CMS
TG Therapeutics, Inc. $124.6604/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136889752 CMS
TG Therapeutics, Inc. $5,737.5004/25/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136889760 CMS
E.R. Squibb & Sons, L.L.C. $124.9904/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101303971 CMS
Mallinckrodt Hospital Products Inc. $13.8604/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145120566 CMS
Ipsen Biopharmaceuticals, Inc $15.8704/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1091978528 CMS
EMD Serono, Inc. $21.4204/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120246311 CMS
TG Therapeutics, Inc. $13.3604/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136889686 CMS
ANI Pharmaceuticals, Inc. $18.6204/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1091164652 CMS
Biogen, Inc. $9.8004/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104835253 CMS
EMD Serono, Inc. $16.9904/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120242333 CMS
TG Therapeutics, Inc. $181.2604/12/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136889778 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $222,254.62 463
PY2020 $116,828.70 138
PY2021 $174,252.41 221
PY2022 $228,926.99 286
PY2023 $211,940.94 287
PY2024 $235,960.41 296
PY2025 $306,145.50 317

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $190,656.92 21
PY2024 Principal investigator $98,076.28 21
PY2023 Principal investigator $46,232.90 12
PY2022 Principal investigator $127,941.04 25
PY2021 Principal investigator $169,756.59 17
PY2020 Principal investigator $347,593.31 11
PY2019 Recipient $536.00 1
PY2019 Principal investigator $296,737.94 20

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

21 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 GENZYME CORPORATION $9,950.00 12/08/2025 Non-covered Recipient Entity
Holy Name Medical Center
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226135964
Principal investigator 1 GENZYME CORPORATION $2,000.00 12/08/2025 Non-covered Recipient Entity
Holy Name Medical Center
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226135968
Principal investigator 1 TG Therapeutics, Inc. $15,275.00 11/30/2025 Non-covered Recipient Entity
Holyname Medical Center, inc.
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226200777
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,236.92 11/19/2025 Non-covered Recipient Entity
HOLY NAME MEDICAL CENTER
A Randomized, Open-label, Parallel-group, Non-inferiority Study Comparing Efficacy, Safety, and Tolerability of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis, Followed by Open-label Treatment With R No dispute reported 06/30/2026 1190308936
Principal investigator 1 TG Therapeutics, Inc. $3,550.00 11/01/2025 Non-covered Recipient Entity
Holyname Medical Center, inc.
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226200773
Principal investigator 1 TG Therapeutics, Inc. $11,250.00 11/01/2025 Non-covered Recipient Entity
Holyname Medical Center, inc.
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226200775
Principal investigator 1 TG Therapeutics, Inc. $21,700.00 10/06/2025 Non-covered Recipient Entity
Holyname Medical Center, inc.
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226200771
Principal investigator 1 TG Therapeutics, Inc. $11,250.00 09/30/2025 Non-covered Recipient Entity
Holyname Medical Center, inc.
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226200747
Principal investigator 1 EMD Serono, Inc. $345.00 09/24/2025 Non-covered Recipient Entity
Advarra, Inc.
Effectiveness of Switching to Cladribine Tablets in Multiple Sclerosis Patients with High Disease Activity or Disease Breakthrough in a US Real-World Population (HDA Switch Study) No dispute reported 06/30/2026 1240118129
Principal investigator 1 F. Hoffmann-La Roche AG $3,803.00 09/22/2025 Non-covered Recipient Entity
HOLY NAME MEDICAL CENTER INC
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211612978
Principal investigator 1 TG Therapeutics, Inc. $10,200.00 08/31/2025 Non-covered Recipient Entity
Holyname Medical Center, inc.
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226200745
Principal investigator 1 GENZYME CORPORATION $35,212.00 08/04/2025 Non-covered Recipient Entity
Holy Name Medical Center
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226135919
Principal investigator 1 TG Therapeutics, Inc. $7,875.00 07/31/2025 Non-covered Recipient Entity
Holyname Medical Center, inc.
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226200743
Principal investigator 1 F. Hoffmann-La Roche AG $241.00 07/23/2025 Non-covered Recipient Entity
HOLY NAME MEDICAL CENTER INC
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211612975
Principal investigator 1 EMD Serono, Inc. $21,196.00 06/23/2025 Non-covered Recipient Entity
Holy Name Medical Center
Effectiveness of Switching to Cladribine Tablets in Multiple Sclerosis Patients with High Disease Activity or Disease Breakthrough in a US Real-World Population (HDA Switch Study) No dispute reported 06/30/2026 1240118353
Principal investigator 1 EMD Serono, Inc. $1,345.00 05/22/2025 Non-covered Recipient Entity
Advarra, Inc.
Effectiveness of Switching to Cladribine Tablets in Multiple Sclerosis Patients with High Disease Activity or Disease Breakthrough in a US Real-World Population (HDA Switch Study) No dispute reported 06/30/2026 1240118121
Principal investigator 1 F. Hoffmann-La Roche AG $8,782.00 04/25/2025 Non-covered Recipient Entity
HOLY NAME MEDICAL CENTER INC
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211612971
Principal investigator 1 EMD Serono, Inc. $1,280.00 03/24/2025 Non-covered Recipient Entity
Advarra, Inc.
Effectiveness of Switching to Cladribine Tablets in Multiple Sclerosis Patients with High Disease Activity or Disease Breakthrough in a US Real-World Population (HDA Switch Study) No dispute reported 06/30/2026 1240118126
Principal investigator 1 GENZYME CORPORATION $16,276.00 02/24/2025 Non-covered Recipient Entity
Holy Name Medical Center Found
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226158050
Principal investigator 1 GENZYME CORPORATION $7,649.00 02/24/2025 Non-covered Recipient Entity
Holy Name Medical Center Found
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226158056
Principal investigator 1 F. Hoffmann-La Roche AG $241.00 01/22/2025 Non-covered Recipient Entity
HOLY NAME MEDICAL CENTER INC
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211612966